



STEMI

247 PROGRAM

DR ALKAMEL

INTERVENTIONAL  
CARDIOLOGIST



# OUTLINES

STEMI DEFINITION  
PATHOPHYSIOLOGY  
EKG

MANAGEMENT  
THROMBOLYTIC VS PRIMARY PCI  
PRIMARY PCI

24/7 PROGRAM  
FASA EXPERIENCE



## Epidimiology



The first cause of mortality all over the world  
in 2017 about 17.5 million died due heart  
disease

in 2030 this number will be 23 milion



**Coronary Heart Disease**

**1 KILLER**

- 
- 
- ➡ 36 % of all mortality in the world due to heart disease
  - ➡ 39 % of all mortality in IRAN due to heart disease
  - ➡ 44% of all mortality in FARS due to heart disease more than any other province in IRAN



# بیشترین علت مرگ ایرانیان در سال ۹۵ چه بوده است؟

منبع: سازمان ثبت احوال

۶۸

میانگین سنی  
فوت شدگان  
زن سال ۱۳۹۵

۶۵

میانگین سنی  
فوت شدگان  
سال ۱۳۹۵

۶۳

میانگین سنی  
فوت شدگان  
مرد سال ۱۳۹۵

۳۶۹۷۵۱

تعداد کل فوت شدگان  
سال ۱۳۹۵

بیشترین سهم چهار علت عمده مرگ و میر در سال ۱۳۹۵ :



۳۹٪



۱۰٪



۸٪



۷٪

خبرگزاری شبستان  
اینفوگرافیک: مهدی دل روشن

زمان ثبت مرگ افراد  
بر حسب فصل



۲۴٪



۲۶٪



۲۴٪



۲۶٪

# Acute Coronary Syndromes

1,360,000 Americans per year

- Unstable Angina

UA



- Non-ST-Segment Elevation MI

NSTEMI



- ST-Segment Elevation MI

STEMI



550,000 /year

530,000 /year

280,000 /year



# DEFINITION

- ▶ STEMI is a clinical syndrome defined by characteristic symptoms of myocardial ischemia in association with persistent electrocardiographic (ECG) ST elevation and subsequent release of biomarkers of myocardial necrosis.



# Anginal “Red Flags”

**Central Anterior Chest Pain**

**Pressure, Tightness, Dull, Crush**

**Radiating to Arms, Neck, Back**

**Approx. 50% ACS Patients**

# Anginal Equivalent “Red Flags”

**Dyspnea**

**Palpitations**

**Syncope**

**Diaphoresis**

**Nausea / Vomiting**




## ECG

- in the proper clinical context, ST-segment elevation (measured at the J-point) is considered suggestive of ongoing coronary artery acute occlusion in the following cases:
- at least two contiguous leads with ST-segment elevation **>2.5 mm in men < 40 years**
- **>2 mm in men >40 years**
- or **>1.5 mm in women** in leads V2–V3 and
- **>1 mm** in the other leads [in the absence of left ventricular (LV) hypertrophy or left bundle branch block **LBBB**]




# Key Features of an ECG






# Example of ST-segment Elevation (STEMI)



# Anatomically Contiguous Leads

<b>I</b> <b>Lateral</b>	<b>aVR</b> <b>Ignore</b>	<b>V1</b> <b>Septal</b>	<b>V4</b> <b>Anterior</b>
<b>II</b> <b>Inferior</b>	<b>aVL</b> <b>Lateral</b>	<b>V2</b> <b>Septal</b>	<b>V5</b> <b>Lateral</b>
<b>III</b>	<b>aVF</b>	<b>V3</b>	<b>V6</b>




# ECG evolution in non-reperfused myocardial infarction

Normal



Peaked T wave



minutes

Progression of  
ST segment elevation



minutes - hours

Loss of R wave,  
Q wave formation



hours - days

T wave inversion




days




## **Table 5** Atypical ECG presentations that deserve prompt management in patients with signs and symptoms of ongoing myocardial ischaemia

- |   |
|---|
| • LBBB  |
| • Ventricular paced rhythm  |
| • Patients without diagnostic ST-segment elevation but with persistent ischaemic symptoms |
| • Isolated posterior myocardial infarction  |
| • ST-segment elevation in lead aVR  |






**“Vulnerable” Plaque**




**“Stable” Plaque**











# Cardiac Compromise




# MANAGEMENT OF Acute Myocardial Infarction





## THE IMPACT OF MEDICAL THERAPY

% Mortality






- 
- 
- The in-hospital mortality of unselected STEMI patients in the national registries of the ESC countries varies between 6% and 14%

## Total ischaemic time

Patient delay

EMS delay

System delay



Patient delay

System delay

## Total ischaemic time



**Table 4**      **Definitions of terms related to reperfusion therapy**

Term	Definition
FMC	The time point when the patient is either initially assessed by a physician, paramedic, nurse or other trained EMS personnel who can obtain and interpret the ECG, and deliver initial interventions (e.g. defibrillation). FMC can be either in the prehospital setting or upon patient arrival at the hospital (e.g. emergency department)
STEMI diagnosis	The time at which the ECG of a patient with ischaemic symptoms is interpreted as presenting ST-segment elevation or equivalent


Primary PCI	Emergent PCI with balloon, stent, or other approved device, performed on the IRA without previous fibrinolytic treatment
Primary PCI strategy	Emergent coronary angiography and PCI of the IRA if indicated
Rescue PCI	Emergent PCI performed as soon as possible in the case of failed fibrinolytic treatment
Routine early PCI strategy after fibrinolysis	Coronary angiography, with PCI of the IRA if indicated, performed between 2 and 24 hours after successful fibrinolysis
Pharmacoinvasive strategy	Fibrinolysis combined with rescue PCI (in case of failed fibrinolysis) or routine early PCI strategy (in case of successful fibrinolysis)

**Table 5** Summary of important time targets

Intervals	Time targets
Maximum time from FMC to ECG and diagnosis <sup>a</sup>	≤10 min
Maximum expected delay from STEMI diagnosis to primary PCI (wire crossing) to choose primary PCI strategy over fibrinolysis (if this target time cannot be met, consider fibrinolysis)	≤120 min
Maximum time from STEMI diagnosis to wire crossing in patients presenting at primary PCI hospitals	≤60 min
Maximum time from STEMI diagnosis to wire crossing in transferred patients	≤90 min
Maximum time from STEMI diagnosis to bolus or infusion start of fibrinolysis in patients unable to meet primary PCI target times	≤10 min
Time delay from start of fibrinolysis to evaluation of its efficacy (success or failure)	60–90 min
Time delay from start of fibrinolysis to angiography (if fibrinolysis is successful)	2–24 hours



# Reperfusion Therapy for Patients with STEMI




\*Patients with cardiogenic shock or severe heart failure initially seen at a non-PCI-capable hospital should be transferred for cardiac catheterization and revascularization as soon as possible, irrespective of time delay from MI onset (Class I, LOE: B). †Angiography and revascularization should not be performed within the first 2 to 3 hours after administration of fibrinolytic therapy.



TIME IS *MUSCLE*


# Minutes mean muscle






# Importance of Rapid Reperfusion in STEMI

*30-minute delay = 8% increase in 1-year mortality*



## NRMI-3-4: Primary PCI



## ➤ The mortality of STEMI is influenced by many factors:

- age
- Killip class
- time delay to treatment
- mode of treatment
- history of prior myocardial infarction
- diabetes mellitus,
- renal failure,
- number of diseased coronary arteries
- ejection fraction, and treatment



## Relief of hypoxaemia and symptoms

Recommendations	Class <sup>a</sup>	Level <sup>b</sup>
<b>Hypoxia</b>		
Oxygen is indicated in patients with hypoxaemia ( $\text{SaO}_2 < 90\%$ or $\text{PaO}_2 < 60$ mmHg).	I	C
Routine oxygen is not recommended in patients with $\text{SaO}_2 \geq 90\%$ . <sup>64–66</sup>	III	B
<b>Symptoms</b>		
Titrated i.v. opioids should be considered to relieve pain.	IIa	C
A mild tranquillizer (usually a benzodiazepine) should be considered in very anxious patients.	IIa	C

# Antiplatelet Therapy to Support Primary PCI for STEMI



A loading dose of a P2Y<sub>12</sub> receptor inhibitor should be given as early as possible or at time of primary PCI to patients with STEMI. Options include:

- Clopidogrel 600 mg; or
- Prasugrel 60 mg; or
- Ticagrelor 180 mg

## therapies in primary PCI

### Antiplatelet therapies

Aspirin	Loading dose of 150–300 mg orally or of 75–250 mg i.v. if oral ingestion is not possible, followed by a maintenance dose of 75–100 mg/day
Clopidogrel	Loading dose of 600 mg orally, followed by a maintenance dose of 75 mg/day
Prasugrel	Loading dose of 60 mg orally, followed by a maintenance dose of 10 mg/day In patients with body weight $\leq 60$ kg, a maintenance dose of 5 mg/day is recommended Prasugrel is contra-indicated in patients with previous stroke. In patients $\geq 75$ years, prasugrel is generally not recommended, but a dose of 5 mg/day should be used if treatment is deemed necessary
Ticagrelor	Loading dose of 180 mg orally, followed by a maintenance dose of 90 mg <i>b.i.d.</i>
Abciximab	Bolus of 0.25 mg/kg i.v. and 0.125 $\mu\text{g/kg/min}$ infusion (maximum 10 $\mu\text{g/min}$ ) for 12 hours
Eptifibatide	Double bolus of 180 $\mu\text{g/kg}$ i.v. (given at a 10-min interval) followed by an infusion of 2.0 $\mu\text{g/kg/min}$ for up to 18 hours
Tirofiban	25 $\mu\text{g/kg}$ over 3 min i.v., followed by a maintenance infusion of 0.15 $\mu\text{g/kg/min}$ for up to 18 hours



**Plavix**

75 mg film-coated tablet Clopidogrel

28 film-coated tablets

**Plavix**

28 film-coated tablets







Clopidogrel 75 mg / daily

Osvix 75 mg / daily

Zylt 75 mg /daily





**75  
mg**

**75  
mg**

**ACTOVERCO**  
**Zyllit® 75**  
Clopidogrel  
28 tablets

# **Zyllit® 75**

## **Clopidogrel**

28 F.C. tablets

Each tablet contains:  
Clopidogrel (as hydrogen sulfate) 75mg

Packaging with blister pack & packaging with  
ACTOVERCO Pharmaceutical Factory, Konya  
Under license of KRKA  
Manufactured by: KRKA, Slovenia

**ACTOVERCO**

**KRKA**

**اسویکس**  
کلوپیโดگرنل

30 F.C. Tablets

**OSVIX**  
Clopidogrel

Each F.C. Tablet Contains:  
Clopidogrel (as hydrogen sulfate) 75 mg  
+ Store below 30°C. Keep in the box.  
+ Protect from moisture and light.  
+ Keep out of the reach of children.

**OSVAH Pharmaceuticals** Tehran-Iran

Batch No.:

Exp. Date:

Price:  
(قیمت برای مصرف کننده)

AN: 11376-102

**OSVIX**  
Clopidogrel

سازمان غذا و دارو  
IFDA  
<http://irc.fda.gov.ir/nfi>

**OSVIX**  
Clopidogrel

**اسویکس**  
کلوپییدوگرل

هر قرص روکشدار محتوی:  
کلوپییدوگرل (به صورت هیدروژن سولفات) ۷۵ میلی گرم  
+ در دمای کمتر از ۳۰ درجه سانتیگراد نگهداری نمایید.  
+ دور از نور و رطوبت و درون جعبه نگهداری نمایید.  
+ دور از دسترس کودکان نگهداری نمایید.  
**OSVAH** شرکت داروسازی اسوه تهران - ایران

فروش بدون نسخه پزشک ممنوع است.  
دستور پزشک:





شماره ثبت دارو (IRC): ۱۲۲۸۰۵۰۶۵۷  
شماره تماس مشتری: ۰۲۱-۸۸۵۶۱۲۶۹  
[www.osvahpharma.com](http://www.osvahpharma.com)

103\*50\*25 mm



# Reperfusion





# Primary PCI



**angioplasty vs thrombolysis**



# Early phase of STEMI

Symptoms onset 0


3 hours

12 hours



Primary  
PCI

I A



I A




**Fibrinolysis**

(only if PCI cannot be performed  
within 120 min from STEMI diagnosis)

Primary  
PCI

I A



I A



**Fibrinolysis**

(only if PCI cannot be performed  
within 120 min from STEMI diagnosis)

**Evolved STEMI**


**12 hours**

**Recent STEMI**

**48 hours**




**Primary PCI**  
(if symptoms,  
hemodynamic instability,  
or arrhythmias)



**I C**


**Primary PCI**  
(asymptomatic  
stable patients)



**IIa B**

**Routine PCI**  
(asymptomatic  
stable patients)

**III A**





# Thrombolytic drugs

- } Streptokinase
- } Urokinase
- } Anistreplase
- } tissue Plasminogen Activators (t-PA)
  - Alteplase
  - Reteplase
  - Tenecteplase



**Table 7**    **Doses of fibrinolytic agents and antithrombotic co-therapies**

Drug	Initial treatment	Specific contra-indications
<b>Doses of fibrinolytic therapy</b>		
Streptokinase	1.5 million units over 30–60 min i.v.	Previous treatment with streptokinase or anistreplase
Alteplase (tPA)	15 mg i.v. bolus 0.75 mg/kg i.v. over 30 min (up to 50 mg) then 0.5 mg/kg i.v. over 60 min (up to 35 mg)	
Reteplase (rPA)	10 units + 10 units i.v. bolus given 30 min apart	
Tenecteplase (TNK-tPA)	Single i.v. bolus: 30 mg (6000 IU) if <60 kg 35 mg (7000 IU) if 60 to <70 kg 40 mg (8000 IU) if 70 to <80 kg 45 mg (9000 IU) if 80 to <90 kg 50 mg (10000 IU) if ≥90 kg It is recommended to reduce to half-dose in patients ≥75 years of age. <sup>121</sup>	

# Thrombolytics for AMI

## Benefits

- Widespread availability
- 12-17% survival benefit
- Preserves LVEF

## Limitations

- 20% of vessels remain occluded
- 45% have TIMI flow < 3
- Median time to reperfusion is 45 minutes
- No reliable marker of reperfusion
- Recurrent ischemia occurs in 15-30%
- Intracranial bleeds occur in 0.5-1.5%

**Table 8**      **Contra-indications to fibrinolytic therapy**

<b>Absolute</b>
Previous intracranial haemorrhage or stroke of unknown origin at anytime
Ischaemic stroke in the preceding 6 months
Central nervous system damage or neoplasms or arteriovenous malformation
Recent major trauma/surgery/head injury (within the preceding month)
Gastrointestinal bleeding within the past month
Known bleeding disorder (excluding menses)
Aortic dissection
Non-compressible punctures in the past 24 hours (e.g. liver biopsy, lumbar puncture)

## Relative

Transient ischaemic attack in the preceding 6 months

Oral anticoagulant therapy

Pregnancy or within 1 week postpartum

Refractory hypertension (SBP >180 mmHg and/or DBP >110 mmHg)

Advanced liver disease

Infective endocarditis

Active peptic ulcer


Prolonged or traumatic resuscitation



# Fibrinolytic therapy

Did save lives compared to placebo, **BUT**


- At best, restored TIMI 3 flow in 55% (rt-PA), +
  - ↑ Incidence of recurrent ischemia and reinfarction
- +**




2 hours  
after t-PA

6 hours  
after t-PA


# PCAT (11 studies, n=2,725): Mortality



# PCAT: Reinfarction




# PCAT: Stroke





# Primary PCI versus Thrombolytics Swedish Heart Intensive Care Registry (RIKS-HIA)



Stenestrand, U. et al. JAMA  
2006;296:1749-1756.


Doses of antiplatelet co-therapies		
Aspirin	Starting dose of 150–300 mg orally (or 75–250 mg intravenously if oral ingestion is not possible), followed by a maintenance dose of 75–100 mg/day	
Clopidogrel	Loading dose of 300 mg orally, followed by a maintenance dose of 75 mg/day. In patients $\geq 75$ years of age: loading dose of 75 mg, followed by a maintenance dose of 75 mg/day.	
Doses of anticoagulant co-therapies		
Enoxaparin	In patients $< 75$ years of age: 30 mg i.v. bolus followed 15 min later by 1 mg/kg s.c. every 12 hours until revascularization or hospital discharge for a maximum of 8 days. The first two s.c. doses should not exceed 100 mg per injection. In patients $\geq 75$ years of age: no i.v. bolus; start with first s.c. dose of 0.75 mg/kg with a maximum of 75 mg per injection for the first two s.c. doses. In patients with $\text{eGFR} < 30 \text{ mL/min/1.73 m}^2$ , regardless of age, the s.c. doses are given once every 24 hours.	
UFH	60 IU/kg i.v. bolus with a maximum of 4000 IU followed by an i.v. infusion of 12 IU/kg with a maximum of 1000 IU/hour for 24–48 hours. Target aPTT: 50–70 s or 1.5 to 2.0 times that of control to be monitored at 3, 6, 12 and 24 hours.	
Fondaparinux (only with streptokinase)	2.5 mg i.v. bolus followed by a s.c. dose of 2.5 mg once daily up to 8 days or hospital discharge.	



# Primary PCI


# The Goal of Primary PCI in STEMI



- Restore flow in the culprit artery and optimize myocardial perfusion (by angio and EKG criteria)
- Preserve LV function.
- Reduce MI complications
- Reduce mortality.





**Left Coronary System has mild CAD. RCA is**









# Mechanical Approaches to Thrombus

## Thrombus aspiration (Rinspirator, Pronto, Export, Rescue, Eliminate, etc.)




## Thrombectomy (AngioJet, X-Sizer)




## Distal protection (GuardWire, FilterWire, AngioGuard, etc.)



FilterWire, An



# THROMBUS ASPIRATION





# Aspiration Thrombectomy in AMI


**Macroscopic embolic debris can be  
retrieved from >80% of cases**





# CHOICE OF STENT





## Monitoring

It is indicated that all STEMI patients have ECG monitoring for a minimum of 24 h.

**I**

**C**

## Length of stay in the CCU

It is indicated that patients with successful reperfusion therapy and an uncomplicated clinical course are kept in the CCU/ICCU for a minimum of 24 h whenever possible, after which they may be moved to a step-down monitored bed for an additional 24–48 h.

**I**

**C**

## Hospital discharge

Early discharge (within 48–72 h) should be considered appropriate in selected low-risk patients<sup>c</sup> if early rehabilitation and adequate follow-up are arranged.<sup>257,259–262,264,265</sup>

**IIa**

**A**



RECOGNIZE







# 247 PROGRAM

- ➡ STARTED AT 1393
- ➡ 30 VOLUNTEER HOSPITALS
- ➡ It means 24 h 7 days we should do primary PCI
- ➡ WE SHOULD NOT GIVE FIBRINOLYTIC TO ANY PATIENT
- ➡ IN FASA IT START AT 11/1394

- 
- 
- Different communities and regions have established programs that coordinate logistical services,
    - pre-hospital emergencies facilities
    - tele-medicine
    - inter-hospital coordination
    - decision making technologiesto improve the management and prognosis of patients with STEMI.

- 
- 
- It need highly coordination between EMS
  - Emergency department
  - Cath lab team
  - Everybody should be sensitive and give importance for the time





# WHO ELIGIBLE TO DO PRIMARY PCI

- Interventional cardiologist who at least do **75** angioplasty per year at least  
**11** of them should be primary PCI

Every hospital should at least **36** primary pci per year



# Technician

- At least have 2 year experience in cath lab or CCU or ICU
- CAN DO advance CPR
- Can work with balloon PUMP




## 247 code

- Person who can activate 247 code
- Interventional cardiologist
- Cardiologist
- Emergency specialist
- Cardiology resident
- internist



وزارت بهداشت، درمان و آموزش پزشکی

شناسنامه استاندارد خدمات  
مدیریت درمان سکته حاد قلبی



کمیته علمی مدیریت درمان سکته حاد قلبی  
معاونت درمان  
مهر ۱۳۹۵





## in hospital management

- The patient with chest pain should take an ECG in less than **10 min**
- The ECG should be seen and interpreted by Emergency specialist in less than **2 min**
- If the diagnosis is dedicated the Emergency specialist should inform the interventional cardiologist and the supervisor
- The physician should tell the patient family about the diagnosis and how it is serious and what are the treatment options
- **The supervisor** should call the cath lab team
- The cath lab team should be in the cath lab in less than **30 min**

At this team the patient should be given

- IV line should be taken from **the left arm** because we use the **right radial** as the main access
- **300mg** of ASA
- **600 mg** OF PLAVIX
- Analgesic like morphine 4mg every 3 -5 min
- O2 if O2sat less than 90%
- Pearl TNG Every 5 min
- Iv beta blocker if the Patient pressure is high

- 
- The patient should CBR
  - DC Shock should be attach to the patient until the patient lay in the cath lap bed
  - If the patient have is intubated or have respiratory distress the anesthesiologist should be present during the hole procedure and until the patient referred to CCU and get stabilized

- 
- ➡ The cath lab nurse should inform CCU about the patient situation to be prepared
  - ➡ When the patient is transferred to CCU DC shock should be attached to him/her
  - ➡ Do not neglect even small details because you can miss the patient easily





# FASA experience


- Primary PCI IN FASA Started before 247 program since 92
- It began systematically at 11/ 94 until now
- We do approximately 950 primary PCI
- We cover all the cities of east of FARS
- We still have a lot of challenges



➡ We still have a big  
matter with **time**



➡ Pain to help 3.5 HOUR = 210 MINUTES



In 1395

- Door to balloon 174
- DOOR TO EKG 65
- STEMI TO Decision 29 m
- Decition to code 42 minutes
- Code to cathlab 26 minutes





in 1399


➡ Door to balloon 66





## referred patient

for patient referred from other cities because it takes along time than usual to send the patient to our hospital it is reasonable to give the patient a fibrinolytic drug and then send them for angioplasty this is called **pharmacoinvasive strategy**





## conclusion

- We need to alert and educate people and personnel about the importance of time in acute MI
- WE SHOULD Support EMS system
- Telemonitoring
- Every body should learn his/her family









■ Thank you for your attention and time